At the Medicap Pharmacy® stores, we are dedicated to providing products and services to care for your family’s wellness. One of those services is health news you can trust. Use the filters to focus on the information that is important to you, then bookmark this page to make it a regular stop anytime you’re online.
Procedure May Lower Parkinson's Pain
Pain is a common symptom of Parkinson's disease, and for many patients, it's an everyday reality. A new procedure, however, could reduce this pain.
Cholesterol, Sugar Guidelines May Change
No cholesterol, yes cholesterol. No coffee, yes coffee. What to eat can get pretty confusing for the average eater. New recommendations may clear up some of that confusion.
Search Still on for Parkinson's Treatments
The search is still on to find effective treatments for Parkinson’s disease. While creatine appeared to be a promising treatment, it now looks like it may be a dud.
The Power of Positive Expectations with Parkinson’s
The mind can be a powerful healer. If patients believe a medication will work, it may boost their health. And new evidence may support this “placebo effect.”
FDA Approves New Parkinson's Treatment
The US Food and Drug Administration (FDA) has approved a new treatment for Parkinson's disease, and it came three months ahead of schedule.
FDA Approves New Pills for Parkinson's
Impax Pharmaceuticals, a division of Impax Laboratories, Inc. (NASDAQ: IPXL), today announced that the U.S. Food and Drug Administration (FDA) approved RYTARY, an extended-release oral capsule formulation of carbidopa-levodopa, for the treatment of Parkinson's disease, post-encephalitic parkinsonism, and parkinsonism that may follow carbon monoxide intoxication and / or manganese intoxication.
A Step Forward for Parkinson’s Patients
Some of the many health benefits of exercise may also apply to patients with Parkinson's. Parkinson's patients who exercise may have improved balance and mobility.
NeuroDerm Parkinson's Rx Shows Promise
NeuroDerm Ltd. (NASDAQ: NDRM), a clinical-stage pharmaceutical company developing drugs for central nervous system (CNS) diseases, today announced that continuous, subcutaneous delivery of the company’s proprietary liquid levodopa/carbidopa (LD/CD) product candidates, ND0612H and ND0612L, led to clinically-significant plasma levodopa levels. These results suggest that the high dose version, ND0612H, intended for severe Parkinson’s disease patients, may provide an effective therapy alternative to current treatments requiring surgery.
Parkinson’s Rx May Trigger Impulse Control Disorders
Dopamine receptor agonists are medicines used to treat the symptoms of Parkinson’s disease. Patients who take them, however, may find themselves having trouble with impulse control.
Migraines Associated With Parkinson’s
Migraines can make daily tasks a challenge. But people who get intense migraines may also face a heightened risk of Parkinson’s disease later in life.